Allergy conjunctivitis market to reach $3.51B by 2030

By AI, Created 9:58 AM UTC, May 20, 2026, /AGP/ – The global allergy conjunctivitis market is projected to rise from $2.63 billion in 2025 to $3.51 billion by 2030, driven by more allergic conditions, broader treatment adoption and digital health channels. North America held the largest share in 2025, while newer therapies and e-commerce are expected to shape the next phase of growth.

Why it matters: - Allergy conjunctivitis affects the conjunctiva and can cause red, itchy, watery eyes that reduce quality of life. - The market’s growth signals rising demand for treatments as allergic eye conditions become more common and more visible to patients and providers. - Broader eye-disorder burden adds pressure for effective care, especially as environmental pollution and chemical exposure contribute to more cases.

What happened: - The Business Research Company published its Allergy Conjunctivitis Global Market Report 2026 on May 7, 2026. - The report says the global allergy conjunctivitis market will grow from $2.63 billion in 2025 to $2.78 billion in 2026. - The report forecasts the market will reach $3.51 billion by 2030. - North America held the largest market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes a free sample and the full market report.

The details: - The market’s 2025-2026 growth rate is 5.9%. - The report projects a 6.0% CAGR through 2030. - Past growth was driven by rising incidence of allergic conditions, limited knowledge of newer treatment options, continued use of traditional antihistamines, uneven healthcare access and heavy reliance on hospital pharmacies. - Future growth is tied to wider adoption of biologics and immunotherapy, more telemedicine use, expansion of pharmaceutical e-commerce, stronger government support for eye care and personalized drug delivery innovations. - Key trends include more seasonal allergies, higher demand for non-steroidal therapies, growth in online pharmacy sales, greater awareness of eye health and preventive care, and expanded allergy programs for pediatric and elderly populations. - Allergy conjunctivitis is an inflammatory condition triggered by allergens such as pollen, mold spores, dust and pet dander. - The condition is defined by inflammation of the conjunctiva, the thin membrane lining the inside of the eyelids and covering the white part of the eye. - The report points to the broader eye-disorder burden as a demand driver. - The World Health Organization said in August 2023 that more than 2.2 billion people globally live with vision impairment. - The World Health Organization said about 1 billion people have major eye conditions causing distance vision problems or blindness, including cataracts, refractive errors, age-related macular degeneration, glaucoma and diabetic retinopathy.

Between the lines: - The market outlook suggests allergy conjunctivitis is moving from a niche seasonal issue to a more structured treatment category. - Growth in telemedicine and online pharmacy channels points to easier access and more self-directed care. - The emphasis on biologics, immunotherapy and personalized delivery suggests treatment is shifting beyond older antihistamine-based care. - The regional lead for North America likely reflects stronger access to diagnosis and treatment, while the broader regional coverage signals uneven growth opportunities globally.

What’s next: - Market growth will likely track adoption of newer therapies, especially biologics and immunotherapy. - Digital care channels and pharmaceutical e-commerce are expected to take a larger role in how patients find and buy treatment. - Eye-care programs targeting children and older adults may become more important as awareness and demand expand. - The report and related materials are available through The Business Research Company, including related market reports on conjunctivitis treatment and bacterial conjunctivitis.